Clinical Trial Update: Luspatercept for Clonal Cytopenias of Uncertain Significance [Phase 2]

View source ↗

Summary

The entry notes an ongoing Phase 2 trial of luspatercept for clonal cytopenias of uncertain significance (CCUS) and related cytopenias such as anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Clonal Cytopenias of Undetermined Significance
• Leukopenia
• Neutropenia
• Thrombocytopenia

Drugs mentioned

• REBLOZYL (LUSPATERCEPT)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: CCUS Clonal Cytopenia of Undetermined Significance, Anemia | Phase 2 | Status: RECRUITING